DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

Dear Dr. Roach: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...

A migraine attack is not just a “bad headache”. Migraine is a debilitating neurological condition which can cause nausea, vomiting, and sensitivity to light or sound, in addition to severe headaches.

Vision changes can happen for a number of reasons, some of which are no major cause for concern, such as dry eye or fatigue. But others are serious enough to warrant a trip to the emergency department ...

Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

If you’ve noticed it’s more difficult to focus on objects up close as you age, you’re not alone. Approximately 128 million Americans suffer from a common form of vision loss—and the number is only ...

What Should You Know About Migraine Medications? There’s no cure for migraine, but treatment can help manage it. Preventive medications aim to reduce how often attacks happen, while rescue medications ...

What Is Yuvezzi, and Why Does It Matter? Yuvezzi is a new prescription eye drop approved to treat presbyopia, a common condition that makes it harder to see things up close as you age. It's the only ...

Ocular Therapeutix (OCUL) added ~21% in the premarket on Thursday after the French publication La Lettre reported that Sanofi (SNY) is readying an improved takeover offer to acquire the U.S. eye ...